Credits Available: 4.25 AMA PRA Category 1 Credits™, 4.25 ANCC Contact Hours, 4.25 ACPE

Description: This dynamic curriculum, detailed by a specialty center clinician, explores each of the CD 19-directed CAR T-cell therapies available for the treatment of DLBCL; solutions to referral and logistic challenges; in-depth early and late toxicity management in CAR T-cell treatment; and the delivery of goal-concordant care using shared decision-making strategies. A challenging real-world case scenario discussion within each Gather-ed group highlights critical decision points, key challenges, and opportunities to incorporate collective insights.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Pharmacist, Physician Assistant, Nurse, Pharmacy Director
Target Specialties: Hematology, Hematology/Oncology, Oncology
Group Leader

Matthew Lunning

University of Nebraska Medical Center
Associate Professor

I work primarily with lymphoma patients in the newly diagnosed and rel/ref settings. I have been active in the development and participation in CAR-T cell trials in multiple NHL diagnoses.

 

Group Co-Leader

Katherine Byar

Nebraska Medicine
Hematological Malignancy Nurse Practitioner

Katherine Byar, MSN, APRN-BC, BMTCN® is an malignant hematology/oncology nurse practitioner at the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska.

Ms. Byar received her Master of Science in Nursing at the University of Nebraska Medical Center. She is certified as an Adult Nurse Practitioner and a Bone Marrow Transplant Certified Nurse.

With more than 30 years of experience and holding a variety of diverse roles in oncology, Katherine is recognized as a national nurse practitioner leader. She is currently working as an outpatient Advance Practice Provider responsible for the care of patients with hematological malignancies. Her clinical expertise includes hematologic malignancies, oncologic emergencies, CAR T-cell therapy, hematopoietic cell transplantation, survivorship, and supportive care. She is a prominent educator who has delivered hundreds of educational presentations to national and international audiences and authored numerous peer-reviewed publications, web courses, and book chapters. Ms. Byar co-edited the “ONS Cancer Basics third edition”. She also is an active member of the Oncology Nursing Society (ONS), and the Advanced Practitioner Society of Hematology and Oncology (APSHO).